On October 11, 2017, we celebrated the AZBio Awards. We invite you to watch the videos to learn more about our AZBio Awards Honorees. Continue reading
Author Archive: AZBio
TGen sequencing test enables precise identification of drug-resistant TB
UCSF and TGen researchers advance SMOR testing, with an eye on precision medicine for tuberculosisContinue reading
Bard Peripheral Vascular named Arizona Bioscience Company of the Year
Bard Peripheral Vascular, a division of C. R. Bard, will be honored for Advancing Lives and the Delivery of Health Care Worldwide at the 2017 AZBio Awards on Oct. 11, 2017.Continue reading
Funded by $21.4 million grant, new NAU research center will address health disparities across Southwest
NAU professor Julie Baldwin, director of the Center for Health Equity Research, and Diane Stearns, NAU associate vice president for research, will co-lead the Southwest Health Equity Research Collaborative.
Ventana Medical Systems Founder Dr. Tom Grogan takes on new role as Founder Emeritus
Dr. Tom Grogan set out on a path to change the practice of medicine 32 years ago when he founded Ventana Medical Systems, Inc., now a global leader in cancer diagnostics that was acquired by Swiss-based Roche Group in 2008. Continue reading
AZBW 2017 Puts Arizona Life Science Innovation In The Spotlight
Arizona Bioscience Week Connects Community and Celebrates One of the Fastest Growing Life Science and Healthcare Sectors in the United States.Continue reading
MIHS, Dignity Health, others form new health education alliance
Maricopa Integrated Health System (MIHS), Creighton University School of Medicine, Dignity Health St. Joseph’s Hospital and Medical Center, and District Medical Group, Inc., have announced a new alliance aimed at increasing the number of doctors and other health professionals in Arizona in order to meet the state’s growing demand for physicians and other healthcare professionals.Continue reading
National Cancer Institute Awards Grant to NuvOx Pharma for Phase II Clinical Trial in Brain Cancer
The National Institutes of Health’s National Cancer Institute (NCI) has awarded a grant for up to $3 million to NuvOx Pharma to initiate a Phase II clinical trial for the investigational drug, NVX-108, in the brain cancer, glioblastoma multiforme (GBM).Continue reading